- Going to BPI West 2017? Don’t miss these great talks and activities!Posted 2 days ago
- Cool Tool – PRIME-XV® T Cell CDM – First Commercially Available Chemically-defined, Animal-component-free Medium for T Cell CulturePosted 4 days ago
- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 1 week ago
- Continuous Processing Optimization with Smarter ToolsPosted 1 week ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 2 weeks ago
- Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic DevelopmentPosted 2 weeks ago
- Cell Culture Dish Top Ten Ask the Expert Sessions and Podcasts of 2016Posted 2 weeks ago
- A Look at the Current State of Continuous BioprocessingPosted 2 weeks ago
- Cool Tool – Biomek i-Series – Next Generation Automated Workstations Specifically Designed to Meet Evolving WorkflowsPosted 3 weeks ago
- Filling Industry Gaps with Dedicated Cell Therapy Fluid Transfer SetsPosted 3 weeks ago
The future of cell culture development? Part II
GEN has a new article that touches on post translational modifications, which one of the major issues facing biomanufacturers, especially those that produce (or hope to produce) biosimilars. As usual glycosylation is the major theme, but the author also touches on deamidation.
Some of the different technologies mentioned include yeast glycoengineering (GlycoFi), a CHO/DG44 line that produces fucose-free antibodies by knocking out the key fucose-adding enzyme (Potelligent cell line), and the greenovation system that uses phototautotrophic moss (add moss to the ever-growing list of organisms currently being pursued as a biopharmaceutical production host organism!).
These are interesting approaches to solve complex problems, but as I have mentioned before, when will any of these type of technologies be used in FDA approved processes? There have been numerous technologies that have tried to vastly improve on the current CHO paradigm (Per.C6 anyone?), but the industry can sometimes be very slow to move, especially when the current system isn’t broken. Many companies instead look to their different development groups (API, cell line, upstream, etc.) and make advances in cell culture media (using supplements or optimized nutrient feeds) , cell lines, and downstream processes instead of switching to a new host organism. It’s difficult to prognosticate which approach will be best, but what do you think will win out?